Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Jun 1st, 2026

LECO_Weekly-Healthcare-News_6-1-2026Download
  1. Healthcare Capital Markets & Innovation Summit (HCMIS 2026) — Day 1 Recap | Theme: “Longevity in Healthcare & Capital Investment” Day 1 of HCMIS 2026 brought together healthcare operators, investors, lenders, innovators, entrepreneurs, and advisors in Columbus, Ohio. The day opened with insights on healthcare deal activity, capital flows, and the state of healthcare credit markets, with a consistent theme: regardless of market conditions, healthcare organizations must continue to innovate, invest, and execute to create long-term value. A fireside discussion with Daryl Tol, President & CEO of HATCo, explored the transformation of health systems and the growing importance of strategic partnerships, innovation platforms, and new operating models. Key discussion tracks included Healthcare Lending & Private Credit, AI & Value-Based Care, Behavioral Health & Health System Innovation, and Healthcare Consumerization. One featured highlight was the “Longevity: Scaling for Healthspan and Lifespan” panel covering preventive care, diagnostics, AI, GLP-1 therapies, and personalized medicine, followed by a lunchtime panel on Longevity as an emerging investment opportunity. The afternoon featured discussions on healthcare M&A, AI in Transactions, Rural Health Innovation, and Strategic Partnerships. New for 2026 was the inaugural Pitch Competition, featuring 13 finalists screened using HDIG’s AI-powered innovation assessment tools, competing for cash prizes, professional services, investment opportunities, and the Blue Jacket Award. (Link)
  2. Eli Lilly (NYSE: LLY) agreed to acquire Seattle-area clinical-stage biotech Curevo Vaccine for up to $1.5 billion in cash — an upfront payment plus a milestone payment — to advance Phase 3-ready next-generation shingles vaccine candidate amezosvatein; Lilly simultaneously announced two additional vaccine acquisitions the same week, bringing total combined consideration to up to ~$3.83 billion Eli Lilly announced on May 26, 2026 agreements to acquire three private vaccine companies simultaneously: Curevo, Inc. (up to $1.5B), LimmaTech Biologics AG (up to $780M), and Vaccine Company, Inc. ($1.55B). Curevo’s lead program, amezosvatein, is a Phase 3-ready adjuvanted subunit shingles vaccine designed to match GSK’s Shingrix on efficacy while reducing side effects by 50%+ in head-to-head Phase 2 data. LimmaTech Biologics is developing vaccines against antimicrobial-resistant bacterial pathogens including S. aureus (LTB-SA7, Phase 1), gonorrhea, and chlamydia. Vaccine Company develops nanoparticle-based vaccines targeting viral diseases. The triple deal signals Lilly’s strategic push into infectious disease prevention using GLP-1 profits, noting common infections are increasingly linked to downstream neurological disease, cancer, and infertility. (Link)
  3. Pfizer (NYSE: PFE) and Suzhou, China-based Innovent Biologics (HK: 01801) entered a global strategic licensing and collaboration agreement for 12 early-stage oncology programs — antibody-drug conjugates and multispecific antibodies — valued at up to $10.5 billion, with $650 million upfront Pfizer and Innovent Biologics announced on May 28, 2026 a strategic global licensing and collaboration agreement covering 12 early-stage cancer medicine programs for up to $10.5 billion. Innovent receives $650 million upfront plus up to $9.85 billion in milestones and double-digit royalties on approved products. The portfolio spans ADCs with novel differentiated payloads and multispecific antibodies with unique immune-engaging designs — eight programs from Innovent, four proposed by Pfizer. The deal is structured in three buckets with varying exclusivity and cost-sharing; Innovent leads Phase 1 trials before Pfizer takes over global development. Innovent shares rose 10%+ in Hong Kong on announcement. One of the largest oncology licensing transactions of 2026, highlighting surging U.S. pharma appetite for Chinese biotech innovation despite geopolitical pressures. (Link)
  4. HCA Healthcare (NYSE: HCA) agreed to acquire The College of Health Care Professions (CHCP), a Texas-based allied health educator with 8,000+ students annually across 10 campuses, to vertically integrate its clinical workforce pipeline HCA Healthcare announced on May 27, 2026 a definitive agreement to acquire The College of Health Care Professions (CHCP), one of the largest allied healthcare training institutions in Texas. CHCP educates more than 8,000 students annually across 10 Texas campuses and online in medical assisting, surgical technology, medical imaging, and allied health programs, and provides continuing education nationwide through its Medical Technology Management Institute. The deal directly addresses the national clinical labor shortage pressuring hospital margins industry-wide. HCA and CHCP have partnered for over a decade through clinical rotations and career placement. Chancellor and CEO Eric Bing will remain to lead CHCP. (Link)
  5. Tractor Supply Company (NASD: TSCO) acquired VIP Petcare veterinary services — the largest provider of mobile veterinary care in the U.S., operating clinics in ~2,700 retail locations across 39 states — from Bansk Group’s PetIQ, bringing vet services in-house across its rural lifestyle retail footprint Tractor Supply Company (NASD: TSCO), the largest rural lifestyle retailer in the U.S., announced on May 28, 2026 it has acquired the veterinary services business VIP Petcare (operating as VIP Petcare and PetVet) from PetIQ, a Bansk Group company. VIP Petcare is the largest provider of mobile veterinary care in the United States, operating community clinics in approximately 2,700 retail locations — including 1,700 locations — across 39 states and serving more than one million pets annually. Bringing VIP Petcare in-house deepens Tractor Supply’s omnichannel pet health platform alongside its Petsense by Tractor Supply stores and Allivet digital pharmacy. (Link)
  6. Mesquite, Texas-based Ernest Health signed a definitive agreement to acquire Reunion Rehabilitation Hospitals — a seven-hospital network across Arizona, Colorado, Texas, and Florida — expanding its footprint from 38 to 45 rehab hospitals Ernest Health, a national post-acute rehabilitation operator, signed a definitive agreement to acquire Reunion Rehabilitation Hospitals, a network of seven medical rehabilitation hospitals in Arizona, Colorado, Texas, and Florida. The deal lifts Ernest’s network from 38 to 45 rehabilitation hospitals nationwide. President and CEO Jake Socha said Reunion’s mission and culture align with Ernest’s locally led hospital model, and the transition will proceed over coming months with no disruption to operations; Reunion employees can remain and join Ernest. (Link)
  7. AI-driven healthcare-engagement platform Swoop acquired prescription-management platform Nimble (NimbleRx) — which serves 16 million patients across independent pharmacies in all 50 states — to add prescription fulfillment and pharmacy connectivity Swoop, an AI-driven, privacy-compliant healthcare marketing platform for life sciences, acquired Nimble (also known as NimbleRx), a prescription-management platform spanning independent pharmacies in all 50 states and enabling 16 million patients to fill, refill, pay for, and manage prescriptions. The combined offering, branded SwoopRx by Nimble, adds prescription fulfillment, pharmacy connectivity, and adherence tools to Swoop’s portfolio. CEO Ron Elwell said the deal extends Swoop “beyond engagement to impact,” while Nimble founder/CEO Talha Sattar emphasized closing the gap between prescription and adherence. Financial terms were not disclosed. The acquisition follows Swoop’s earlier purchase of MyHealthTeam. (Link)
  8. Chicago-based private credit manager Monroe Capital acted as lead arranger and administrative agent on a senior credit facility backing private equity sponsor Warburg Pincus’ investment in Waco, Texas-based home-based care provider Cornerstone Caregiving (terms undisclosed). Monroe Capital LLC arranged and administered a senior credit facility to support private equity firm Warburg Pincus’ investment in Cornerstone Caregiving, a Waco, Texas home-based care provider founded in 2020 that offers hospice, home care, palliative care, and senior services (including Alzheimer’s and dementia care) across hundreds of U.S. locations; financial terms were not disclosed. Monroe framed the deal as continued PE appetite for non-acute, lower-cost care delivery as hospitals and insurers shift volume out of institutional settings. Warburg Pincus, founded in 1971, has invested over $130 billion across 1,100-plus companies; the financing adds to Chicago-based Monroe’s growing healthcare-services private credit portfolio. (Link)
  9. Cleveland, Ohio- and Dallas-based private equity firm Align Capital Partners (ACP) acquired Heritage Imaging, a mobile diagnostic imaging provider serving hospitals across 14 states, as a new platform investment Align Capital Partners (ACP), a lower-middle-market PE firm headquartered in Cleveland, Ohio (Shaker Heights) and Dallas with $2.1 billion in committed capital, acquired Heritage Imaging as its next platform. Founded in 1989, Heritage provides fully staffed mobile diagnostic imaging — PET/CT, MRI, nuclear medicine, ultrasound and echocardiography — to hospitals across 14 states, focusing on rural and underserved markets. CEO Dr. Steve Coppess and the management team stay on. ACP’s Rob Langley led the deal and plans further M&A in outsourced imaging; Heritage has closed three add-ons since 2024. (Link)
  10. Baltimore, Maryland-based Procare Ambulance entered a strategic partnership with Prodos Capital and Manolin Investment Group — with growth capital from Tecum Capital, Genesis Park Capital, and SharpVue Capital — to expand its Mid-Atlantic emergency and non-emergency interfacility transport and Mobile Integrated Health platform Procare Ambulance of Maryland, a Baltimore-based provider of non-emergency and emergency interfacility transportation (IFT) services serving the Maryland and Washington, D.C. markets with recent expansion into Virginia, entered a strategic partnership with Prodos Capital and Manolin Investment Group on June 1, 2026. Tecum Capital, Genesis Park Capital, and SharpVue Capital provided growth capital to support the partnership. Procare delivers Basic Life Support, Advanced Life Support, Specialty and Critical Care Transport, Mobile Integrated Health (MIH), and medical standby services to a roster of healthcare institutions across the Mid-Atlantic. Founder Debbie Ailiff and CEO Mark Bucholtz will remain to lead the business; the partnership will support geographic expansion into Virginia, development of the MIH program, and investment in workforce and fleet. (Link)
  11. New Hyde Park, NY-based Premier Care Dental Management (PCDM) acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio led by Ohio Dental Association President-Elect Dr. Brett Pelok, deepening PCDM’s Ohio presence Premier Care Dental Management (PCDM), a multi-state Dental Clinical Organization, acquired Brett Pelok, DDS & Associates, a general dental practice in Toledo, Ohio. The practice is owned by Dr. Brett Pelok, President-Elect of the Ohio Dental Association, who will continue leading clinical care post-transaction. CEO and founder Dr. Scott Asnis said the deal supports PCDM’s growth while letting the practice keep its identity and clinical leadership. PCDM operates across NY, CT, NJ, PA, OH, NH, MA, and RI. (Link)
  12. Chicago-based, doctor-owned PE platform Phase 1 Equity added a multi-site orthodontic practice in Texas — its third practice acquisition of 2026 — bringing the network to 21 doctors and 31 locations Phase 1 Equity, a Chicago-based doctor-owned, doctor-led PE platform for orthodontists and pediatric dentists, added another multi-site orthodontic practice in Texas. This marks its third practice addition of 2026, its third in Texas, its 21st affiliated doctor, and lifts total locations to 31. CEO Mike Rice cited continued momentum as more doctors recognize the platform’s value. Doctors retain clinical control while gaining shared services and PE-style resources. (Link)
  13. MorningStar Senior Living recapitalized its 112-unit Houston assisted-living and memory-care community, River Oaks, with TPG Angelo Gordon U.S. Real Estate, retaining long-term management of the Class-A property MorningStar Senior Living recapitalized MorningStar at River Oaks, a Class-A, 112-unit assisted-living and memory-care community in Houston, with investor TPG Angelo Gordon U.S. Real Estate. MorningStar co-developed the community (opened 2021) and will continue managing it under a long-term agreement, deepening its relationship with TPG Angelo Gordon. MorningStar’s portfolio spans 38 communities (operating or in development), 5,000+ units across 11 states. (Link)
  14. Tokyo-based Olympus Corporation agreed to acquire Tel Aviv-area VC-backed MedTech company BioProtect Ltd. for $270 million, adding a prostate cancer radiation spacer device to its urology and oncology portfolio Olympus Corporation announced on May 26, 2026 a definitive agreement to acquire Israel-based BioProtect Ltd. (backed by MVM Partners) for $270 million. BioProtect’s Balloon Spacer is an implantable hydrogel that creates a temporary physical barrier between the prostate and rectum during radiation therapy, reducing healthy-tissue exposure and improving treatment precision in prostate cancer — the second most commonly diagnosed cancer in men globally (~1.5 million new cases/year). The deal extends Olympus’ oncology and urology portfolio adjacent to its core endoscopy platform, consistent with its “Innovation-Driven Growth” strategy. (Link)
  15. Bain Capital agreed to sell Australian residential aged-care provider Estia Health to alternative investment firm Stonepeak, exiting an asset it grew from 73 to 93 homes since 2023 Bain Capital signed an agreement to sell Estia Health, one of Australia’s leading residential aged-care providers, to alternative investment firm Stonepeak; financial terms were not disclosed. Bain Capital acquired Estia in December 2023 and, over its hold, grew the business from 73 homes serving ~6,720 residents to 93 homes serving ~9,250 residents, with more than 14,000 employees. The Bain investment was led by Australia-based partners Mike Murphy, Charles Lawson, and Grace Mollard. The transaction is expected to close in late 2026, subject to regulatory approvals. Bain Capital manages approximately $225 billion in assets across its global platform. (Link)
  16. Dallas, Texas-based PE firm Highlander Partners backed the merger of Bucharest-based MONZA-ARES — Romania’s leading private cardiology and complex surgery hospital group — with Brain Institute, the country’s premier private neurosurgery center, to form one of Romania’s leading private hospital operators MONZA-ARES, Romania’s leading private hospital group focused on cardiology and complex surgery, and Brain Institute, the country’s premier private neurosurgery center, announced on May 26, 2026 they are combining operations to create one of Romania’s leading private healthcare platforms. The merged group is backed by Dallas-based private equity firm Highlander Partners (managing over $3 billion in assets), which has held a majority stake in MONZA-ARES since 2019. The expanded group spans cardiology, neurosurgery, ENT, orthopedics, thoracic surgery, general surgery, and gynecology across facilities in Bucharest, Cluj-Napoca, Constanța, Târgu Jiu, Tulcea, and Onești. Brain Institute shareholders are reinvesting into the combined group. Raiffeisen Bank Romania provided acquisition financing. (Link)
  17. Basel, Switzerland-based CDMO CordenPharma (PE: Astorg) to acquire North Augusta, South Carolina- and Shanghai-based peptide API CDMO AmbioPharm, adding ~400 employees and expanding global peptide manufacturing platform across three continents CordenPharma, the Basel-based global CDMO majority-owned by pan-European PE firm Astorg since 2022, announced on May 27, 2026 an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO with facilities in North Augusta, South Carolina and Shanghai, China. AmbioPharm employs approximately 400 people across its two sites and brings SPPS, LPPS, and hybrid peptide synthesis capabilities that complement CordenPharma’s proprietary Tag-Assisted Peptide Synthesis (TAPS). The North Augusta site becomes CordenPharma’s second U.S. peptide facility, adding purification and lyophilization capacity; the Shanghai campus is CordenPharma’s first Asia-based production footprint. The deal gives pharma customers fully U.S.-based or global supply options for complex, long-chain peptide APIs — strategically timed given rising GLP-1 peptide demand. CordenPharma generated €960 million in sales and employs more than 3,000 across its 11-site network. AmbioPharm shareholders will reinvest into the combined business. (Link)

Venture Deals and Other

  1. Garner Health, a digital care-navigation platform for employers, closed a $100 million Series E at a $2.74 billion valuation led by Index Ventures, with existing backers Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures Garner Health closed a $100 million Series E led by Index Ventures, with existing investors Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures participating, pushing its valuation to $2.74 billion. The round comes just three months after a $118 million Series D. Index partner Jahanvi Sardana praised Garner for making physician quality measurable via AI. The startup, which uses 60 billion-plus medical records to rank providers and steers ~2.5 million members across nearly 800 clients to high performers, will fund its provider-quality platform, AI product development, and member expansion. (Link)
  2. Healthcare data platform H1 secured a $40 million round led by CVS Health Ventures, the corporate venture arm of CVS Health (NYSE: CVS), validating that profitable, data-centric SaaS startups can still attract capital H1, a nine-year-old healthcare data platform that sells detailed physician information to pharma, hospital systems, and insurers, secured $40 million led by CVS Health Ventures, the corporate VC arm of CVS Health (NYSE: CVS). CEO Ariel Katz said H1 wasn’t seeking capital — the company turned cash-flow and EBITDA profitable last year and projects 40%+ growth — but found partnering with a major healthcare player compelling. H1 was last valued at $750 million in a 2021 round led by Altimeter Capital, and acquired Veda and Ribbon Health and grown. (Link)
  3. San Diego-based ClearNote Health closed a $52 million Series D — led by founding investor Mattias Westman — to scale its blood-based early detection tests for pancreatic and ovarian cancer, bringing total funding to $185 million+ ClearNote Health closed a $52 million Series D on May 27, 2026, led by founding investor Mattias Westman with participation from former Citigroup CEO Sandy Weill, Stanford co-founder Dr. Stephen Quake, and institutional investors, bringing total funding to more than $185 million. ClearNote’s Avantect tests use multiomic blood analysis and machine learning to detect pancreatic and ovarian cancers at early stages — two cancers with very limited detection options and poor late-stage survival rates. The company’s multi-cancer detection test was selected for the NCI’s Vanguard Study. Kevin Keegan — formerly GM of Oncology at Illumina and senior leader at BD and Hologic — joined as President and COO alongside the close. (Link)
  4. Oncology-AI startup Triomics raised $22 million in Series B funding led by Battery Ventures, with returning backers Nexus Venture Partners, Lightspeed, and Y Combinator, to bring oncology-specific AI to cancer centers Triomics raised $22 million in a Series B led by Battery Ventures, with returning investors Nexus Venture Partners, Lightspeed, and Y Combinator participating. Founded in 2021, the startup builds oncology-specific AI to automate data-heavy tasks like clinical-trial matching, patient summaries, and tumor-registry reporting; it previously raised a $15 million Series A in mid-2024. Co-founder Sarim Khan said models trained on oncology data win institutions like Memorial Sloan Kettering and Yale Cancer Center over generic scribes such as Abridge and Microsoft’s Nuance. Triomics grew its enterprise base fourfold and recurring revenue tenfold over the past year. (Link)
  5. Silicon Valley metabolic-health startup Signos raised $20 million — with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating — to expand its FDA-cleared continuous glucose monitoring platform for weight management Signos raised $20 million to scale its glucose-monitoring platform for weight loss, with Dexcom (NASDAQ: DXCM), Blue Cross Blue Shield of Alabama, and GV (Google Ventures) participating; the round brings total funding to $57 million since 2018. Signos pairs Dexcom’s over-the-counter Stelo sensor with an AI-powered app delivering personalized diet and lifestyle guidance. Investors view it as complementary to GLP-1 drugs, helping users sustain results through behavior change. CEO Sharam Fouladgar-Mercer said the company is targeting self-insured employers as its primary growth channel as it deploys the new capital. (Link)
  6. Plano, Texas-based Secretome Therapeutics closed a $30 million Series A — with RA Capital Management as the sole investor — to advance STM-01, an nCPC-derived therapy for Duchenne muscular dystrophy cardiomyopathy, into pivotal trials Secretome Therapeutics closed a $30 million Series A on May 27, 2026 with RA Capital Management as the sole investor. Proceeds advance STM-01, a therapy derived from neonatal cardiac progenitor cells (nCPCs) targeting Duchenne muscular dystrophy-associated cardiomyopathy — a leading cause of mortality in DMD patients with very few disease-modifying treatment options. The company intends to move STM-01 into pivotal Phase 2 and Phase 3 development. DMD affects approximately 1 in 3,500–5,000 male births globally. RA Capital’s sole-investor structure signals exceptional conviction in the program’s differentiated biology. Former Ra Pharmaceuticals CFO David Lubner joined the Board alongside the close. (Link)
  7. New York-based Solstice, an AI-native pharma commercialization platform, raised $21 million in Series A funding led by Transformation Capital — with Twelve Below and Virtue Ventures participating — to accelerate MLR review compression from months to days Solstice raised $21 million in Series A financing announced May 28, 2026, led by Transformation Capital with Twelve Below, Virtue Ventures, and others, bringing total funding to approximately $25 million. Biopharma companies spend more than $100 billion annually on commercialization, yet medical, legal, and regulatory (MLR) review cycles can stretch three months for routine marketing assets. Solstice compresses that timeline to under 10 days through AI-native content creation, automated regulatory review, fair balance scoring, and performance tracking in a single compliant workflow. The company already serves over a dozen pharma brands including several top-20 global names. (Link)
  8. Boston-based sleep-tech startup SOND exited stealth with $7 million from E14 Fund, Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele to launch its closed-loop Dreambuds sleep earbuds SOND, founded by MIT grads including Bose’s former Head of Global Sleep Yadid Ayzenberg, emerged from stealth with $7 million from E14 Fund (MIT-affiliated), Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele. The funding accompanies its debut product, Dreambuds — closed-loop in-ear devices capturing 12 physiological signals and feeding a cloud-based AI sleep coach. SOND aims for mass production by Q2 2026 following a planned crowdfunding campaign, and is currently taking reservations. (Link)
  9. New York-based Kubera Health raised $6.5 million in seed funding led by Upfront Ventures — with Company Ventures, Dria Ventures, and SemperVirens participating — to build the contract-to-payment infrastructure layer for U.S. healthcare Kubera Health raised $6.5 million in seed funding announced May 28, 2026, led by Upfront Ventures with Company Ventures, Dria Ventures, and SemperVirens participating. Founded by physician-executive Roja Garimella, MD, MBA, Kubera is building the contract-to-payment system of record for American healthcare — translating complex payor-provider contracts and fee schedules into structured, continuously auditable logic running against claims and payment data in real time. The AMA estimates one in five commercial claims is processed inaccurately, contributing to roughly $1 trillion in annual administrative burden. Early enterprise customers including Hollywood Presbyterian Medical Center have expanded their engagements. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities

CLICK HERE